Agios Pharmaceuticals
AGIO
27.60
-1.16
-4.03%
Agios Pharmaceuticals
US · AGIO
#2841 by market cap
Listed 1970
27.60
-1.16
-4.03%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
B-
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: RBC Capital moved from Buy to Hold on 2026-02-12.
Analyst consensus 6 analysts
Buy
Avg price target 45.80 +65.9%
Price target rangecurrent 27.60
Low32.00
Avg45.80
High62.00
Buy 67%
Hold 33%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-06 | BofA Securities | -- | Buy | 48.00 |
| 2026-11-06 | Truist Financial | -- | Buy | 35.00 |
| 2026-11-06 | H.C. Wainwright | -- | Buy | 62.00 |
| 2026-11-05 | Truist Financial | -- | Buy | 35.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-11-05 | RBC Capital | -- | Hold | 32.00 |
| 2026-11-02 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-10-31 | J.P. Morgan | -- | Hold | -- |
| 2026-10-30 | BofA Securities | -- | Buy | 50.00 |
| 2026-10-30 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-10-29 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-10-28 | Citi | -- | Buy | 52.00 |
| 2026-10-08 | RBC Capital | -- | Hold | 32.00 |
| 2026-10-07 | Truist Financial | -- | Buy | 37.00 |
| 2026-10-06 | BofA Securities | -- | Buy | 50.00 |
| 2026-09-21 | BofA Securities | -- | Buy | 50.00 |
| 2026-08-11 | Truist Financial | -- | Buy | -- |
| 2026-08-03 | TD Cowen | -- | Buy | -- |
| 2026-07-31 | Truist Financial | -- | Buy | 39.00 |
| 2026-07-31 | Citi | -- | Buy | 52.00 |
| 2026-07-30 | TD Cowen | -- | Buy | -- |
| 2026-07-30 | BofA Securities | -- | Buy | 46.00 |
| 2026-07-30 | Citi | -- | Buy | 52.00 |
| 2026-07-30 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-07-22 | BofA Securities | -- | Buy | 46.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-02-12 | RBC Capital | Buy → Hold | 28.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-05 | -- | ±9.00% | -9.91% (beat) |
| 2026/Q2 | 2026-07-30 | -- | ±9.54% | -6.46% (in line) |
| 2026/Q1 | 2026-04-29 | -- | ±8.47% | +13.10% (beat) |
| 2025/Q4 | 2026-02-12 | -- | ±12.45% | +1.30% (in line) |
| 2025/Q3 | 2025-10-30 | -- | ±16.58% | +2.91% (in line) |
| 2025/Q2 | 2025-07-31 | -- | ±11.40% | -0.85% (in line) |
| 2025/Q1 | 2025-05-01 | -- | ±21.61% | +4.21% (in line) |
| 2024/Q4 | 2025-02-13 | -- | ±8.31% | +1.49% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±15.71% | -4.04% (in line) |
| 2024/Q2 | 2024-08-01 | -- | ±13.46% | -4.09% (in line) |
| 2024/Q1 | 2024-05-02 | -- | ±13.65% | +2.73% (in line) |
| 2023/Q4 | 2024-02-15 | -- | ±8.96% | +3.47% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Agios Pharmaceuticals discussion 0 comments